SurVaxM is engineered to be highly immunogenic, and is delivered through simple subcutaneous injection. Read More
Survivin is an endogenous cellular protein that prevents tumor cell death. It is not, however, generally present in normal adult cells. Survivin is the target of MimiVax SurVaxM.
MimiVax Immunotherapy: SurVaxM
Elm & Carlton Streets
Buffalo, NY 14263
Pharmaceuticals for Oncology
MimiVax, LLC together with Roswell Park Cancer Institute will be presenting the results of their recently completed Phase I clinical study of SurVaxM in recurrent glioma patients at the 2015 American Association for Cancer Research Annual Meeting (AACR).
"Phase I study of SurVaxM in patients with survivin-expressing recurrent malignant gliomas" - Abstract CT301
(Tuesday, Apr 21, 2015, 8:00AM-12:00PM; Poster Section 24, Board #1) www.AACR.org